Completed PHASE2 INTERVENTIONAL 2-arm NCT05660616

Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma

Switch-Maintenance Gemcitabine After First-Line Chemotherapy (Pemetrexed-Platinum) In Patients With Malignant Pleural Mesothelioma In Ain Shams University Hospitals

Sponsor: Ain Shams University

Conditions Malignant Pleural Mesothelioma

Interventions Gemcitabine supportive care

Updated 5 times since 2023 Last updated: Aug 25, 2024 Started: Apr 1, 2023 Primary completion: Apr 1, 2024 Completion: Apr 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Malignant Pleural Mesothelioma and is currently completed. Ain Shams University leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2023 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting · Phase: PHASE3 → PHASE2
Mar 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE3
Jan 2023 — Mar 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ain Shams University

Data source: Ain Shams University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt